Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life

Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the clinical value of prophylaxis, real-world experience with prophylaxis, and patient quality-of-life...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Miguel A., Leissinger, Cindy, Young, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236157/
https://www.ncbi.nlm.nih.gov/pubmed/35769336
http://dx.doi.org/10.6004/jadpro.2022.13.4.8
_version_ 1784736470705111040
author Escobar, Miguel A.
Leissinger, Cindy
Young, Guy
author_facet Escobar, Miguel A.
Leissinger, Cindy
Young, Guy
author_sort Escobar, Miguel A.
collection PubMed
description Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the clinical value of prophylaxis, real-world experience with prophylaxis, and patient quality-of-life factors that must be considered when choosing treatment options for these patients.
format Online
Article
Text
id pubmed-9236157
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-92361572022-06-28 Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life Escobar, Miguel A. Leissinger, Cindy Young, Guy J Adv Pract Oncol Review Hemophilia A is a rare inherited bleeding disorder characterized by a deficiency in factor VIII. The evolution of currently approved prophylaxis therapy in hemophilia A will be reviewed, including the clinical value of prophylaxis, real-world experience with prophylaxis, and patient quality-of-life factors that must be considered when choosing treatment options for these patients. Harborside Press LLC 2022-05 2022-06-21 /pmc/articles/PMC9236157/ /pubmed/35769336 http://dx.doi.org/10.6004/jadpro.2022.13.4.8 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Escobar, Miguel A.
Leissinger, Cindy
Young, Guy
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title_full Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title_fullStr Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title_full_unstemmed Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title_short Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
title_sort hemophilia a: strategies for improving long-term holistic management, adherence, and quality of life
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9236157/
https://www.ncbi.nlm.nih.gov/pubmed/35769336
http://dx.doi.org/10.6004/jadpro.2022.13.4.8
work_keys_str_mv AT escobarmiguela hemophiliaastrategiesforimprovinglongtermholisticmanagementadherenceandqualityoflife
AT leissingercindy hemophiliaastrategiesforimprovinglongtermholisticmanagementadherenceandqualityoflife
AT youngguy hemophiliaastrategiesforimprovinglongtermholisticmanagementadherenceandqualityoflife

Ejemplares similares